endra_10q.htm

0001681682false--12-31Q120240.00018000000010390150109144470.00010.00010.00011000010001000000000141340000

All per share amounts and number of shares in the consolidated financial statements and related notes have been retroactively restated to reflect the Reverse Split (as defined and described under Note 7 below).

000016816822024-01-012024-03-310001681682us-gaap:SubsequentEventMemberndra:NasdaqMarketplaceRuleOneMember2024-05-012024-05-030001681682us-gaap:SubsequentEventMember2024-05-012024-05-030001681682ndra:JanuaryOneTwentyFifteenMember2024-01-012024-03-310001681682ndra:JanuaryOneTwentyFifteenMember2021-03-012021-03-150001681682ndra:JanuaryOneTwentyFifteenMember2017-10-012017-10-100001681682ndra:EmploymentAgreementsMemberndra:MichaelThorntonMember2017-05-012017-05-120001681682ndra:EmploymentAgreementsMemberndra:MichaelThorntonMember2019-04-012019-04-150001681682ndra:EmploymentAgreementsMemberndra:FrancoisMichelonMember2017-05-012017-05-120001681682ndra:EmploymentAgreementsMemberndra:MichaelThorntonMember2024-01-012024-03-310001681682ndra:EmploymentAgreementsMemberndra:FrancoisMichelonMember2024-01-012024-03-310001681682ndra:MrTokmanMember2023-10-012023-10-170001681682srt:MinimumMember2023-05-020001681682srt:MaximumMember2023-05-0200016816822023-05-0200016816822023-05-012023-05-020001681682ndra:WarrantsMember2024-01-012024-03-310001681682srt:MaximumMember2024-01-012024-03-310001681682srt:MinimumMember2024-01-012024-03-310001681682ndra:BlackScholesMertonOptionPricingModelMembersrt:MaximumMember2024-01-012024-03-310001681682ndra:BlackScholesMertonOptionPricingModelMembersrt:MinimumMember2024-01-012024-03-3100016816822023-11-300001681682us-gaap:SeriesAPreferredStockMember2024-01-012024-03-310001681682us-gaap:RestrictedStockMember2024-01-012024-03-310001681682ndra:JuneTwentyTwentyOneATMAgreementMember2021-06-012021-06-210001681682ndra:TheOfferingMember2024-01-012024-03-310001681682ndra:JuneTwentyTwentyOneATMAgreementMember2024-01-012024-03-310001681682ndra:JuneTwentyTwentyOneATMAgreementMember2021-06-210001681682ndra:JuneTwentyTwentyOneATMAgreementMember2024-03-310001681682us-gaap:SeriesCPreferredStockMember2024-03-310001681682us-gaap:SeriesBPreferredStockMember2024-03-310001681682ndra:TDBankLoanMember2020-04-012020-04-270001681682ndra:TDBankLoanMember2023-12-310001681682ndra:TDBankLoanMember2020-04-270001681682ndra:TDBankLoanMember2024-03-310001681682ndra:SharesIssuableUponConversionOfSeriesAConvertiblePreferredStockMember2024-01-012024-03-310001681682ndra:SharesIssuableUponConversionOfSeriesAConvertiblePreferredStockMember2023-01-012023-12-310001681682ndra:WarrantsToPurchaseCommonStockMember2024-01-012024-03-310001681682ndra:WarrantsToPurchaseCommonStockMember2023-01-012023-12-310001681682ndra:OptionsToPurchaseCommonStockMember2024-01-012024-03-310001681682ndra:OptionsToPurchaseCommonStockMember2023-01-012023-12-3100016816822023-01-012023-12-310001681682us-gaap:RetainedEarningsMember2024-03-310001681682ndra:StockPayableMember2024-03-310001681682us-gaap:AdditionalPaidInCapitalMember2024-03-310001681682us-gaap:CommonStockMember2024-03-310001681682ndra:ConvertiblePreferredStockSeriesAMember2024-03-310001681682us-gaap:RetainedEarningsMember2024-01-012024-03-310001681682ndra:StockPayableMember2024-01-012024-03-310001681682us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-310001681682us-gaap:CommonStockMember2024-01-012024-03-310001681682ndra:ConvertiblePreferredStockSeriesAMember2024-01-012024-03-310001681682us-gaap:RetainedEarningsMember2023-12-310001681682ndra:StockPayableMember2023-12-310001681682us-gaap:AdditionalPaidInCapitalMember2023-12-310001681682us-gaap:CommonStockMember2023-12-310001681682ndra:ConvertiblePreferredStockSeriesAMember2023-12-3100016816822023-03-310001681682us-gaap:RetainedEarningsMember2023-03-310001681682ndra:StockPayableMember2023-03-310001681682us-gaap:AdditionalPaidInCapitalMember2023-03-310001681682us-gaap:CommonStockMember2023-03-310001681682ndra:ConvertiblePreferredStockSeriesAMember2023-03-310001681682us-gaap:RetainedEarningsMember2023-01-012023-03-310001681682ndra:StockPayableMember2023-01-012023-03-310001681682us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310001681682us-gaap:CommonStockMember2023-01-012023-03-310001681682ndra:ConvertiblePreferredStockSeriesAMember2023-01-012023-03-3100016816822022-12-310001681682us-gaap:RetainedEarningsMember2022-12-310001681682ndra:StockPayableMember2022-12-310001681682us-gaap:AdditionalPaidInCapitalMember2022-12-310001681682us-gaap:CommonStockMember2022-12-310001681682ndra:ConvertiblePreferredStockSeriesAMember2022-12-3100016816822023-01-012023-03-310001681682ndra:SeriesAConvertiblePreferredStockMember2023-12-310001681682ndra:SeriesAConvertiblePreferredStockMember2024-03-310001681682ndra:SeriesCConvertiblePreferredStockMember2023-12-310001681682ndra:SeriesCConvertiblePreferredStockMember2024-03-310001681682ndra:SeriesBConvertiblePreferredStockMember2023-12-310001681682ndra:SeriesBConvertiblePreferredStockMember2024-03-310001681682us-gaap:SeriesAPreferredStockMember2023-12-310001681682us-gaap:SeriesAPreferredStockMember2024-03-3100016816822023-12-3100016816822024-03-3100016816822024-05-14iso4217:USDxbrli:sharesiso4217:USDxbrli:sharesxbrli:pureiso4217:CADutr:sqft

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act:

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of May 14, 2024, there were 11,035,659 shares of our common stock, par value $0.0001 per share, outstanding.

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

As used in this Quarterly Report on Form 10-Q (this “Form 10-Q”), unless the context otherwise requires, the terms “we,” “us,” “our,” “ENDRA” and the “Company” refer to ENDRA Life Sciences Inc., a Delaware corporation, and its direct and indirect subsidiaries. The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our historical financial statements and related notes thereto in this Form 10-Q. This Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be covered by the “safe harbor” created by those sections. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as “believe,” “expect,” “may,” “will,” “should,” “could,” “would,” “seek,” “intend,” “plan,” “estimate,” “anticipate” or other comparable terms. All statements other than statements of historical facts included in this Form 10-Q, including those regarding our strategies, prospects, financial condition, operations, costs, plans and objectives, are forward-looking statements. Examples of forward-looking statements include, among others, statements we make regarding expectations for revenues, cash flows and financial performance, the anticipated results of our development efforts and the timing for receipt of required regulatory approvals and product launches. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in, or implied by, the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: our limited commercial experience, limited cash and history of losses; our ability to obtain adequate financing to fund our business operations in the future; our ability to achieve profitability; our ability to develop a commercially feasible application based on our Thermo-Acoustic Enhanced Ultrasound (“TAEUS”) technology; market acceptance of our technology; uncertainties associated with any future pandemic, including possible effects on our operations; results of our human studies, which may be negative or inconclusive; our ability to find and maintain development partners; our reliance on collaborations and strategic alliances and licensing arrangements; the amount and nature of competition in our industry; our ability to protect our intellectual property; potential changes in the healthcare industry or third-party reimbursement practices; delays and changes in regulatory requirements, policy and guidelines including potential delays in submitting required regulatory applications for Food and Drug Administration (“FDA”) approval; our ability to obtain and maintain CE mark certification and secure required FDA and other governmental approvals for our TAEUS applications; our ability to comply with regulation by various federal, state, local and foreign governmental agencies and to maintain necessary regulatory clearances or approvals; and the other risks and uncertainties described in the Risk Factors section of our Annual Report on Form 10-K for the period ended December 31, 2023, as filed with the SEC on March 28, 2024, and in the Management’s Discussion and Analysis of Financial Condition and Results of Operations section of this Form 10-Q. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

From time to time, we use press releases, Twitter (@endralifesci) and LinkedIn (www.linkedin.com/company/endra-inc) to distribute material information. Our press releases and financial and other material information are routinely posted to and accessible on the Investors section of our website, www.endrainc.com. Accordingly, investors should monitor these channels, in addition to our SEC filings and public conference calls and webcasts. In addition, investors may automatically receive e-mail alerts and other information about the Company by enrolling their e-mail addresses by visiting the “Email Alerts” section of our website at investors.endrainc.com. Information that is contained in and can be accessed through our website, Twitter posts and LinkedIn are not incorporated into, and do not form a part of, this Quarterly Report or any other report or document we file with the SEC.

We are leveraging experience with pre-clinical enhanced ultrasound devices to develop technology for increasing the capabilities of clinical diagnostic ultrasound and other types of capital equipment, to broaden patient access to the safe diagnosis and treatment of a number of significant medical conditions in circumstances where expensive X-ray CT and MRI technology, or other diagnostic technologies such as surgical biopsy, are unavailable or impractical. Building on our expertise in thermoacoustics, we have developed a next-generation technology platform-Thermo Acoustic Enhanced Ultrasound, or TAEUS-which is intended to enhance the capability of clinical ultrasound technology and support the diagnosis and treatment of a number of significant medical conditions that currently require the use of expensive CT or MRI imaging or where imaging is not practical using existing technology.

The first-generation TAEUS application is a standalone ultrasound accessory designed to cost-effectively quantify fat in the liver and stage progression of nonalcoholic fatty liver disease (“NAFLD”), which can otherwise only be achieved today with impractical surgical biopsies or MRI scans. Subsequent TAEUS offerings are expected to be implemented via a second-generation hardware platform that can run multiple clinical software applications that we will offer TAEUS users for a licensing fee-adding ongoing customer value to the TAEUS platform and a growing software revenue stream for our Company.

Each of our TAEUS platform applications will require regulatory approvals before we are able to sell or license the application. Based on certain factors, such as the installed base of ultrasound systems, availability of other imaging technologies, such as CT and MRI, economic strength and applicable regulatory requirements, we intend to seek initial approval of our applications for sale in the European Union and the United States, followed by China.

In March 2020, we received CE mark approval for our TAEUS FLIP (“Fatty Liver Imaging Probe”) System, enabling its marketing and sales in the European Union and other CE mark geographies, including the 27 EU member states.

In June 2020, we submitted a 510(k) Application to the FDA for our TAEUS Fatty Live Imaging Probe (“FLIP”) System. In February 2022, we announced that we would pursue FDA reclassification and clearance of our TAEUS FLIP System through the FDA’s “de novo” process. We subsequently voluntarily withdrew our 510(k) Application submitted a de novo request for the TAEUS system to the FDA in the third quarter of 2023. In the fourth quarter of 2023, the FDA sent us an AI request related to our de novo application. Since we received the AI request, we have had several interactions with the FDA and have provided additional information. In order to fully respond to the FDA’s questions, we will need to compile additional clinical data, provide additional device test data, and respond to cybersecurity related questions in a new de novo submission. We have a scheduled in-person pre-submission meeting with the FDA in the second quarter of 2024. We currently anticipate completing the necessary clinical studies by the fourth quarter of 2024 and submitting the new de novo request to the FDA in the first half of 2025.

No revenue has been generated by our TAEUS technology, which we have not commercially sold as of March 31, 2024.

Our research and development expenses primarily include wages, fees and equipment for the development of our TAEUS technology platform and the proposed applications. Additionally, we incur certain costs associated with the protection of our products and inventions through a combination of patents, licenses, applications and disclosures. These costs and expenses include:

We plan to incur research and development expenses for the foreseeable future as we expect to continue the development of TAEUS and pursue FDA approval of the NAFLD TAEUS system. At this time, due to the inherently unpredictable nature of clinical development and regulatory approvals, we are unable to estimate with certainty the costs we will incur and the timelines we will require in our continued development efforts.

Sales and marketing expenses consist primarily of headcount and consulting costs, and marketing and tradeshow expenses. Currently, our marketing efforts are through our website and attendance of key industry meetings and conferences. In connection with the commercialization of our TAEUS applications, we are building a small sales and marketing team to train and support global ultrasound distributors and expect to execute traditional marketing activities such as promotional materials, electronic media and participation in industry events and conferences. As of March 31, 2024, we had a full-time sales representative in each of the United Kingdom, France and Germany. We expect to add to our sales representation and support headcount for operations in the EU as resources permit in the future, and plan to begin staffing our sales efforts in the United States once we have obtained FDA approval for the sale of the NAFLD TAEUS device in that region.

General and administrative expenses consist primarily of salaries and related expenses for our management and personnel, and professional fees, such as for accounting, consulting and legal services. We anticipate that our general and administrative expenses will increase in the future as we support our continued research and development activities, expand our sales and marketing operations, and continue as a public company. These increases would likely include increased costs related to the hiring of personnel, including compensation and employee-related expenses, including stock-based compensation, and fees to outside consultants, lawyers and accountants, among other expenses. Additionally, we anticipate continued costs associated with being a public company, including expenses related to services associated with maintaining compliance with The Nasdaq Capital Market and SEC requirements, directors and officers insurance, increased legal and accounting costs and investor relations costs.

The preparation of the financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.

Management makes estimates that affect certain accounts including deferred income tax assets, accrued expenses, fair value of equity instruments and reserves for any other commitments or contingencies. Any adjustments applied to estimates are recognized in the period in which such adjustments are determined.

Our Omnibus Plan permits the grant of stock options and other stock awards to our employees, consultants and non-employee members of our board of directors. Each January 1 the pool of shares available for issuance under the Omnibus Plan automatically increases by an amount equal to the lesser of (i) the number of shares necessary such that the aggregate number of shares available under the Omnibus Plan equals 25% of the number of fully-diluted outstanding shares on the increase date (assuming the conversion of all outstanding shares of preferred stock and other outstanding convertible securities and exercise of all outstanding options and warrants to purchase shares) and (ii) if the board of directors takes action to set a lower amount, the amount determined by the board. On January 1, 2024, the pool of shares issuable under the Omnibus Plan automatically increased by 1,717,783 shares from 1,322,169 shares to 3,039,952 shares. As of March 31, 2024, there were 2,360,665 shares of common stock remaining available for issuance under the Omnibus Plan.

We record share-based compensation in accordance with the provisions of the Share-based Compensation Topic of the FASB Codification. The guidance requires the use of option-pricing models that require the input of highly subjective assumptions, including the option’s expected life and the price volatility of the underlying stock. The fair value of each option grant is estimated on the date of grant using the Black-Scholes option valuation model which uses certain assumptions related to risk-free interest rates, expected volatility, expected life of the common stock options, and future dividends, and the resulting charge is expensed using the straight-line attribution method over the vesting period.

See Note 2 of the accompanying financial statements for a discussion of recently issued accounting standards.

We had no cost of goods sold during the three months ended March 31, 2024 and 2023.

Research and development expenses were $1,041,526 for the three months ended March 31, 2024, as compared to $1,391,314 for the three months ended March 31, 2023, a decrease of $349,788 or 25%. The costs include primarily wages, fees and equipment for the development of our TAEUS product line. Research and development expenses decreased from the prior year as we completed development of our initial TAEUS product and began focusing our spending on commercialization of the product that has been developed.

Sales and marketing expenses were $238,660 for the three months ended March 31, 2024, as compared to $181,616 for the three months ended March 31, 2023, an increase of $57,044, or 31%. The costs include primarily headcount and pre-selling activities for our TAEUS product line. Sales and marketing expenses increased largely due to the increase in consulting fees. Currently, our marketing efforts are through our website and attendance of key industry meetings.

Our general and administrative expenses for the three months ended March 31, 2024 were $1,500,355, compared to $1,366,398 for the three months ended March 31, 2023, an increase of $133,957, or 10%. Our wage and related expenses for the three months ended March 31, 2024 were $641,381, compared to $611,819 for the three months ended March 31, 2023. Wage and related expenses in the three months ended March 31, 2024 included $165,121 of stock compensation expense related to the issuance and vesting of options, compared to $77,865 of stock compensation expense related to the issuance and vesting of options, for the three months ended March 31, 2023. Our professional fees, which include legal, audit, and investor relations, for the three months ended March 31, 2024 were $639,872, compared to $520,637 for the three months ended March 31, 2023.

As a result of the foregoing, for the three months ended March 31, 2024, we recorded a net loss of $2,775,700, compared to a net loss of $2,942,746 for the three months ended March 31, 2023.

We are experiencing financial and operating challenges. In the absence of immediate additional liquidity, we will be forced to delay or reduce our product development programs and commercialization efforts, materially curtail or cease our operations, sell or dispose of our rights or assets, pursue sale or other strategic transactions, or undergo restructuring or insolvency proceedings. As of March 31, 2024, we had an accumulated deficit of $94,705,852 and had $1,134,701 in cash. To date we have funded our operations through private and public sales of our securities and will need to raise additional funds in order to execute on our business plan, fully commercialize our TAEUS technology, and generate revenues.

We need additional capital to allow us to continue to execute our commercialization plans through the second quarter of 2024. We are considering potential financing options that may be available to us, such as sales of our common stock, including through our at-the-market sales program (the “ATM Program”) with Ascendiant Capital Markets, LLC. Except for the ATM Program, we have no commitments to obtain any additional funds, and there can be no assurance funds will be available in sufficient amounts or on acceptable terms. If we are unable to obtain sufficient additional financing in a timely fashion and on terms acceptable to us, our financial condition and results of operations may be materially adversely affected and we may not be able to continue operations or execute our stated commercialization plan.

The consolidated financial statements included in this Form 10-Q have been prepared assuming we will continue as a going concern, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. As reflected in the accompanying consolidated financial statements, during the three months ended March 31, 2024, we incurred net losses of $2,775,700 and used cash in operations of $2,144,312. In light of our cash balance as of March 31, 2024, we will need to raise additional capital in order to fund operations through the next twelve months, and prior to any ability to fund operations from revenue generated from the sale of our products. The financial statements do not include any adjustments that might be necessary should we be unable to continue as a going concern.

During the three months ended March 31, 2024, we used $2,144,312 of cash in operating activities primarily as a result of our net loss of $2,775,700, offset by share-based compensation of $317,497, amortization of right of use assets of $40,376, inventory reserve of $142,733, depreciation expense of $15,300, fixed assets write-off of $8,808, and net changes in operating assets and liabilities of $106,674.

During the three months ended March 31, 2023, we used $2,506,847 of cash in operating activities primarily as a result of our net loss of $2,942,746, offset by share-based compensation of $237,279, depreciation expense of $34,516, amortization of right of use assets of $36,526, and net changes in operating assets and liabilities of $127,578.

During the three months ended March 31, 2024, we used $27,000 in investing activities related to purchases of fixed assets, and received $3,204 in proceeds from sale of fixed assets.

During the three months ended March 31, 2023, we used $27,000 in investing activities related to purchases of fixed assets.

During the three months ended March 31, 2024, our financing activities provided $419,967 in proceeds from issuances of common stock, $77,419 in proceeds from warrant exercises. We also used $28,484 to repay a loan from TD Bank under the Canadian Emergency Business Account.

During the three months ended March 31, 2023, there were no financing activities.

We have not completed the commercialization of any of our TAEUS technology platform applications. We expect to continue to incur significant expenses for the foreseeable future. We anticipate that our expenses will increase substantially as we:

It is possible that we will not achieve the progress that we expect because the actual costs and timing of completing the development and regulatory approvals for a new medical device are difficult to predict and are subject to substantial risks and delays. We have no committed external sources of funds except for the February 2024 ATM Agreement, the use of which may be limited due to registration statement rules relating to public float. We do not expect that our existing cash will be sufficient for us to complete the commercialization of our NAFLD TAEUS application or to complete the development of any other TAEUS application and we will need to raise substantial additional capital for those purposes. As a result, we will need to finance our future cash needs through public or private equity offerings, debt financings, corporate collaboration and licensing arrangements or other financing alternatives. Our forecast of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement and involves risks and uncertainties, and actual results could vary as a result of a number of factors, including the factors discussed in the Risk Factors section of this Annual Report on Form 10-K. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect.

Until we can generate a sufficient amount of revenue from our TAEUS platform applications, if ever, we expect to finance future cash needs through public or private equity offerings, debt financings or corporate collaborations and licensing arrangements. Additional funds may not be available when we need them on terms that are acceptable to us, or at all. If adequate funds are not available, we may be required to delay, reduce the scope of or eliminate one or more of our research or development programs or our commercialization efforts or perhaps even cease the operation of our business. To the extent that we raise additional funds by issuing equity securities, our stockholders may experience additional dilution, and debt financing, if available, may involve restrictive covenants. To the extent that we raise additional funds through collaborations and licensing arrangements, it may be necessary to relinquish some rights to our technologies or applications or grant licenses on terms that may not be favorable to us. We may seek to access the public or private capital markets whenever conditions are favorable, even if we do not have an immediate need for additional capital at that time.

At March 31, 2024, the Company did not have any transactions, obligations or relationships that could be considered off-balance sheet arrangements.

As a smaller reporting company, we are not required to provide the information required by this Item 3.

As of the end of the period covered by this Form 10-Q, management performed, with the participation of our principal executive officer and principal financial officer, an evaluation of the effectiveness of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”). Our disclosure controls and procedures are designed to ensure that information required to be disclosed in the reports we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC’s forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, to allow timely decisions regarding required disclosures. Based on the evaluation, our principal executive officer and principal financial officer concluded that, as of March 31, 2024, our disclosure controls and procedures were not effective.

A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis. We identified the following material weakness as of March 31, 2024: insufficient personnel resources within the accounting function to segregate the duties over financial transaction processing and reporting.

To remediate the material weakness, management intends to implement the following measures during 2024, as the Company’s resources and financial means allow:

The additional hiring is contingent upon our efforts to obtain additional funding and the results of our operations.

There were no changes to our internal control over financial reporting or in other factors that could affect these controls during the three months ended March 31, 2024 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

We are not currently a party to any pending legal proceedings that we believe will have a material adverse effect on our business or financial condition. We may, however, be subject to various claims and legal actions arising in the ordinary course of business from time to time.

In addition to the other information set forth in this report, you should carefully consider the factors discussed in this section and under “Risk Factors” in our Annual Report on Form 10-K for the period ended December 31, 2023, as filed with the Securities and Exchange Commission on March 28, 2024. These factors could materially adversely affect our business, financial condition, liquidity, results of operations and capital position, and could cause our actual results to differ materially from our historical results or the results contemplated by any forward-looking statements contained in this report.

We have a history of operating losses and will need to raise significant additional capital to continue our business and operations. If we are unable to raise sufficient capital in the near term to meet our capital and operating needs, we may be forced to further delay, reduce or eliminate our operating activities, or cease operations entirely, which would have a material adverse effect on our business and cause stockholders to lose all of their investment.

We are experiencing financial and operating challenges. As of March 31, 2024, we had $1.1 million of cash and cash equivalents. As disclosed in our auditor’s report on our financial statements filed with our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, there is substantial doubt about our ability to continue as a going concern and, to remain viable, we will require significant additional liquidity in order to execute our business plan. Any inability to raise adequate funds on commercially reasonable terms and in the near term would have a material adverse effect on our business, results of operation and financial condition, including the possibility that a lack of funds causes our business to fail and liquidate.

Item 2. Recent Sales of Unregistered Securities; Use of Proceeds from Registered Securities

None of the Company’s directors or officers adopted, modified, or terminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement during the Company’s fiscal quarter ended March 31, 2024.

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Delaware		26-0579295
(State of incorporation)		(I.R.S. Employer Identification No.)

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		NDRA		The Nasdaq Stock Market LLC

		Page
PART I - FINANCIAL INFORMATION

Item 1.	Condensed Consolidated Financial Statements (unaudited)	3

	Condensed Consolidated Balance Sheets - March 31, 2024 (unaudited) and December 31, 2023	3

	Condensed Consolidated Statements of Operations - Three months Ended March 31, 2024 and 2023 (unaudited)	4

	Condensed Consolidated Statements of Stockholders’ Equity - Three months Ended March 31, 2024 and 2023 (unaudited)	5

	Condensed Consolidated Statements of Cash Flows - Three months Ended March 31, 2024 and 2023 (unaudited)	6

	Notes to the Condensed Consolidated Financial Statements (unaudited)	7

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	15

Item 3.	Quantitative and Qualitative Disclosures About Market Risk	20

Item 4.	Controls and Procedures	20

Item 1.	Legal Proceedings	21

Item1A.	Risk Factors	21

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	21

Item 3.	Defaults Upon Senior Securities	21

Item 4.	Mine Safety Disclosure	21

Item 5.	Other Information	21

Item 6.	Exhibits	22

	Signatures	23

	March 31,			December 31,
Assets	2024			2023
Current Assets	(unaudited)
Cash	$	1,134,701		$	2,833,907
Prepaid expenses		135,821			198,905
Total Current Assets		1,270,522			3,032,812
Non-Current Assets
Inventory		2,711,923			2,622,865
Fixed assets, net		111,470			111,782
Right of use assets		313,715			354,091
Prepaid expenses, long term		647,085			626,610
Other assets		5,986			5,986
Total Assets	$	5,060,701		$	6,754,146

Liabilities and Stockholders’ Equity
Current Liabilities
Accounts payable and accrued liabilities	$	1,038,465		$	700,754
Lease liabilities, current portion		178,239			173,857
Loans		-			28,484
Total Current Liabilities		1,216,704			903,095

Long Term Debt
Loans, long term		-			-
Lease liabilities		145,825			192,062
Total Long Term Debt		145,825			192,062

Total Liabilities		1,362,529			1,095,157

Stockholders’ Equity
Series A Convertible Preferred Stock, $0.0001 par value; 10,000 shares authorized; 34.976 and 141.397 shares issued and outstanding		-			1
Series B Convertible Preferred Stock, $0.0001 par value; 1,000 shares authorized; no shares issued and outstanding		-			-
Series C Convertible Preferred Stock, $0.0001 par value; 100,000 shares authorized; no shares issued and outstanding		-			-
Common stock, $0.0001 par value; 80,000,000 shares authorized; 10,914,447 and 10,390,150 shares issued and outstanding, respectively		1,092			1,039
Additional paid in capital		98,402,631			97,582,868
Stock payable		301			5,233
Accumulated deficit		(94,705,852	)		(91,930,152	)
Total Stockholders’ Equity		3,698,172			5,658,989
Total Liabilities and Stockholders’ Equity	$	5,060,701		$	6,754,146

	Three Months Ended			Three Months Ended
	March 31,			March 31,
	2024			2023
Operating Expenses
Research and development	$	1,041,526		$	1,391,314
Sales and marketing		238,660			181,616
General and administrative		1,500,355			1,366,398
Total operating expenses		2,780,541			2,939,328

Operating loss		(2,780,541	)		(2,939,328	)

Other Expenses
Other income (expense)		4,841			(3,418	)
Total other expenses		4,841			(3,418	)

Loss from operations before income taxes		(2,775,700	)		(2,942,746	)

Provision for income taxes		-			-

Net Loss	$	(2,775,700	)	$	(2,942,746	)

Net loss per share – basic and diluted	$	(0.26	)	$	(0.93	)

Weighted average common shares – basic and diluted		10,804,625			3,169,103

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated Filer	☒	Smaller reporting company	☒
		Emerging growth company	☐

*Three Months Ended March 31, 2023*	Series A Convertible								Additional								Total
	Preferred Stock				Common stock				Paid in					Accumulated			Stockholders'
	Shares		Amount		Shares		Amount		Capital		Stock Payable			Deficit			Equity
Balance as of December 31, 2022		141.397	$	1		3,169,103	$	317	$	89,068,015		6,073			(81,869,902	)		7,204,504
Fair value of vested stock options		-		-		-		-		237,279		-			-			237,279
Stock payable towards preference dividend		-		-		-		-		2,381		(2,381	)		-			-
Net loss		-		-		-		-		-		-			(2,942,746	)		(2,942,746	)
Balance as of March 31, 2023		141.397	$	1		3,169,103	$	317	$	89,307,675	$	3,692		$	(84,812,648	)		4,499,037

*Three Months Ended March 31, 2024*	Series A Convertible										Additional								Total
	Preferred Stock						Common stock				Paid in					Accumulated			Stockholders'
	Shares			Amount			Shares		Amount		Capital		Stock Payable			Deficit			Equity
Balance as of December 31, 2023		141.397		$	1			10,390,150	$	1,039	$	97,582,868		5,233			(91,930,152	)		5,658,989
Preferred stock conversion to common stock		(106.421	)		(1	)		7,622		1		-		-			-			-
Common stock issued for cash		-			-			316,963		32		419,935		-			-			419,967
Common stock issued for warrant exercise		-			-			118,904		12		77,407		-			-			77,419
Fair value of vested common stock for services		-			-			80,808		8		79,992		-			-			80,000
Fair value of vested stock options		-			-			-		-		237,497		-			-			237,497
Stock payable towards preference dividend		-			-			-		-		4,932		(4,932	)		-			-
Net loss		-			-			-		-		-		-			(2,775,700	)		(2,775,700	)
Balance as of March 31, 2024		34.976		$	-			10,914,447	$	1,092	$	98,402,631	$	301		$	(94,705,852	)	$	3,698,172

	March 31, 2024		December 31, 2023
Options to purchase common stock		679,287		624,240
Warrants to purchase common stock		763,445		882,349
Shares issuable upon conversion of Series A Convertible Preferred Stock		2,010		8,126
Potential equivalent shares excluded		1,444,742		1,514,715

·	Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets;

·	Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and

·	Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.

	March 31, 2024			December 31, 2023
Property, leasehold and capitalized software	$	590,955		$	587,030
TAEUS development and testing		125,151			125,151
Accumulated depreciation		(604,636	)		(600,399	)
Fixed assets, net	$	111,470		$	111,782

	March 31, 2024		December 31, 2023
Accounts payable	$	521,577	$	360,401
Accrued payroll		266,058		150,293
Accrued bonuses		154,122		35,518
Accrued employee benefits		5,750		5,750
Insurance premium financing		90,958		148,792
Total	$	1,038,465	$	700,754

	Number of Options			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (Years)
Balance outstanding at December 31, 2023		624,240		$	19.25		7.26
Granted		55,346			2.06		7.93
Exercised		-			-		-
Forfeited		-			-		-
Cancelled or expired		(299	)		31.96		-
Balance outstanding at March 31, 2024		679,287		$	17.83		7.09
Exercisable at March 31, 2024		402,162		$	22.57		6.15

	Number of Warrants			Weighted Average Exercise Price		Weighted Average Contractual Term (Years)
Balance outstanding at December 31, 2023		882,349		$	1.58		3.79
Granted		-			-		-
Exercised		(118,904	)		0.70		4.09
Forfeited		-			-		-
Expired		-			-		-
Balance outstanding at March 31, 2024		763,445		$	1.60		3.47
Exercisable at March 31, 2024		763,445		$	1.60		3.47

	Operating Lease
2024		151,968
2025 and beyond		202,624
Total	$	354,592
Less: amount representing interest		(30,527	)
Present value of future minimum lease payments		324,064
Less: current obligations under leases		(178,240	)
Long-term lease obligations	$	145,825

·	employee-related expenses, such as salaries, bonuses and benefits, consultant-related expenses such as consultant fees and bonuses, stock-based compensation, overhead related expenses and travel-related expenses for our research and development personnel;

·	expenses incurred under agreements with contract research organizations (“CROs”), contract manufacturing organizations (“CMOs”) as well as consultants that support the implementation of our clinical and non-clinical studies;

·	manufacturing and packaging costs in connection with conducting clinical trials;

·	formulation, research and development expenses related to our TAEUS technology; and

·	costs for sponsored research.

	·	advance the engineering design and development of our TAEUS technology;

	·	acquire parts and build finished goods inventory of the TAEUS FLIP system;

	·	complete regulatory filings required for marketing approval of our NAFLD TAEUS application in the United States, including clinical studies to advance our de novo application with the FDA;

	·	seek to hire a small internal marketing team to engage and support channel partners and clinical customers for our NAFLD TAEUS application;

	·	expand marketing of our NAFLD TAEUS application;

	·	advance development of our other TAEUS applications; and

	·	add operational, financial and management information systems and personnel, including personnel to support our product development, planned commercialization efforts and our operation as a public company.

·	Add additional accounting personnel or outside consultants, such as a new controller, to properly segregate duties and to effect timely, accurate preparation of the financial statements; and

·	Continue the development of adequate written accounting policies and procedures.

Exhibit Number		Description
3.1		Fourth Amended and Restated Certificate of Incorporation of the Company (incorporated by reference to Exhibit 3.2 to the Company’s Current Report on Form 8-K filed on May 12, 2017)
3.2		Certificate of Amendment to the Fourth Amended and Restated Certificate of Incorporation of the Company (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed on June 18, 2020)
3.3		Amended and Restated Bylaws of the Company (incorporated by reference to Exhibit 3.4 to the Company’s Registration Statement on Form S-1 (File No. 333-214724), as amended, originally filed on November 21, 2016)
31.1		Certification of Periodic Report by Chief Executive Officer pursuant to Rule 13a-14(a)/15d-14a and pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith)
31.2		Certification of Periodic Report by Principal Financial Officer pursuant to Rule 13a-14(a)/15d-14a and pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith)
32.1		Certification of Periodic Report by Chief Executive Officer and Principal Financial Officer pursuant to U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (furnished herewith)
101.INS		XBRL Instance Document (filed herewith)
101.SCH		XBRL Taxonomy Schema (filed herewith)
101.CAL		XBRL Taxonomy Extension Calculation Linkbase (filed herewith)
101.DEF		XBRL Taxonomy Extension Definition Linkbase (filed herewith)
101.LAB		XBRL Taxonomy Extension Label Linkbase (filed herewith)
101.PRE		XBRL Taxonomy Extension Presentation Linkbase (filed herewith)

	ENDRA LIFE SCIENCES INC.

Date: May 14, 2024	By:	/s/ Francois Michelon
		Francois Michelon
		Chief Executive Officer and Chairman (Principal Executive Officer)

	ENDRA LIFE SCIENCES INC.

Date: May 14, 2024	By:	/s/ Irina Pestrikova
		Irina Pestrikova
		Senior Director, Finance (Principal Financial and Accounting Officer)